The Federal Council of Medicine (CFM) has banned doctors from using PMMA for aesthetic and repairing purposes across Brazil [1].

The decision marks a significant shift in the country's regulatory approach to dermal fillers. By restricting the use of polymethyl methacrylate, the governing body aims to reduce the incidence of severe complications associated with the permanent filler, which has been a subject of medical concern due to its long-term effects on tissue.

The prohibition takes effect on Tuesday, June 2, 2026 [2]. The CFM said that the risks associated with the substance far outweigh the potential benefits when used for cosmetic or reconstructive goals [1].

While the ban is comprehensive, the CFM established a specific medical exception. The use of PMMA remains permitted only for the treatment of lipodystrophy in patients with HIV/AIDS [3]. To ensure safety and oversight, these specific procedures must be performed within high-complexity units accredited by the Unified Health System (SUS) [3].

Medical professionals throughout the national territory must now comply with these restrictions or face regulatory action [1]. The move follows an evaluation of the safety profile of the material and its impact on patient health [1].

"The risks far outweigh the benefits," the Federal Council of Medicine said [1].

Regarding the implementation date, the Council said, "The CFM prohibits the medical use of PMMA starting this Tuesday (2)" [2].

On the narrow exception for HIV/AIDS patients, the Council said, "The only exception permitted by the CFM is for the treatment of lipodystrophy in patients with HIV/AIDS, which must be carried out in high-complexity units accredited by the SUS" [3].

“"The risks far outweigh the benefits."”

This ban reflects an increasing global medical trend toward prioritizing patient safety over permanent cosmetic enhancements. By limiting PMMA to specific clinical needs within the public health system, Brazil is effectively removing a high-risk permanent filler from the commercial aesthetic market to prevent long-term complications that are often difficult to reverse surgically.